Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jasper, A.
Right arrow Articles by Koerner, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jasper, A.
Right arrow Articles by Koerner, S.

Chest, Vol 91, 614-618, Copyright © 1987 by American College of Chest Physicians

ARTICLES

Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients

AC Jasper, Z Mohsenifar, S Kahan, HS Goldberg and SK Koerner

We compared two modes of aerosol bronchodilator delivery in 34 patients hospitalized with obstructive airways diseases. The standard mode, therapist-administered up-draft nebulization (UDN), is labor-intensive and therefore relatively costly. The alternative mode, self- administration by a metered dose inhaler (MDI), is less costly, but its efficacy over an entire hospitalization has heretofore not been established. Patients were enrolled after transfer to the pulmonary ward from the emergency room or intensive care units (ICU). We then randomized them to receive metaproterenol q4h either via MDI or UDN. Daily spirometry revealed that MDI and UDN were associated with equivalent bronchodilation initially and equivalent improvement at discharge. The duration of hospitalization for the two groups was also the same. Thus, the two delivery methods were equally effective. We could not attribute this equivalence to pretreatment intergroup differences or to differences in concomitant therapy with steroids, theophylline, other bronchodilators, or antibiotics. Routine use of MDI rather than UDN in all non-ICU adult patients would save $253,487 per year at our institution alone.


This article has been cited by other articles:


Home page
 BMJHome page
S. Schneeweiss, M. Maclure, B. Carleton, R. J Glynn, and J. Avorn
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations
BMJ, March 6, 2004; 328(7439): 560.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S S Garner, D B Wiest, J W Bradley, and D M Habib
Two administration methods for inhaled salbutamol in intubated patients
Arch. Dis. Child., July 1, 2002; 87(1): 49 - 53.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. C. McCrory, C. Brown, S. E. Gelfand, and P. B. Bach
Management of Acute Exacerbations of COPD : A Summary and Appraisal of Published Evidence
Chest, April 1, 2001; 119(4): 1190 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
Management of patients with asthma in the emergency department and in hospital
Can. Med. Assoc. J., November 1, 1999; 161(90111): s53 - 59.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American College of Chest Physicians.